Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous
AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other di...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 12; no. 10; pp. 1621 - 1625 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan
14.03.2006
Baishideng Publishing Group Co., Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).
METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA.
RESULTS: CF in active UC was strikingly high compared with all other groups (x^2〈0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (x^2〈0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation.
CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. |
---|---|
AbstractList | AIMTo investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODSCF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA.RESULTSCF in active UC was strikingly high compared with all other groups (c2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (c2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation.CONCLUSIONElevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. RESULTS: CF in active UC was strikingly high compared with all other groups (χ 2 <0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (χ 2 <0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. CF in active UC was strikingly high compared with all other groups (c2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (c2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. RESULTS: CF in active UC was strikingly high compared with all other groups (x^2〈0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (x^2〈0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. R5; AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA.RESULTS: CF in active UC was strikingly high compared with all other groups (χ2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (χ2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate,suggesting that elevated CF was not a consequence of acute inflammation.CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance)and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD. |
Author | Koji Sawada Ryouki Takahashi Abbi R Saniabadi Maiko Ohdo Takashi Shimoyama |
AuthorAffiliation | Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan Japan Immunoresearch Laboratories.Takasaki, Japan |
AuthorAffiliation_xml | – name: Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan |
Author_xml | – sequence: 1 givenname: Koji surname: Sawada fullname: Sawada, Koji email: f-sawada@leaf.ocn.ne.jp organization: Department of Gastroenterology, Fujimoto Hospital Medicine, 3-15-27 Konda Habikino, Osaka 583-0857, Japan. f-sawada@leaf.ocn.ne.jp – sequence: 2 givenname: Ryouki surname: Takahashi fullname: Takahashi, Ryouki – sequence: 3 givenname: Abbi R surname: Saniabadi fullname: Saniabadi, Abbi R – sequence: 4 givenname: Maiko surname: Ohdo fullname: Ohdo, Maiko – sequence: 5 givenname: Takashi surname: Shimoyama fullname: Shimoyama, Takashi |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16570358$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUU1rGzEUFCWhcdLeeypLKb2to8_V6lIIIf2AQC7pWX2rldZydyVHWtv431fGph8nwXszo5k31-gixGARekfwkkne3u7Xw3JH6NKXAWkoeYUWlBJV05bjC7QgGMtaMSqv0HXOa4wpY4K-RlekERIz0S7Qz4fR7mC2fbUZIU9QmXSIznfJhzjYUPlQbWD2Nsy52vt5VYGZ_c6WuRthmmCO6VB1cW_HqvfZQi6rXE0xdb7Q4za_QZcOxmzfnt8b9OPLw_P9t_rx6ev3-7vH2nCB59o5EKLjTlBlWqp6Z3pCrKOsYdhw1vOucVJCI2yJ2QqQinSuA9oyylsFwG7Q55PuZttNtjfFcYJRb5KfIB10BK__3wS_0kPcaU4op6otAh9PAnsIDsKg13GbQrGsy5Upxk25JsUF9un8T4ovW5tnPfls7DhCsCWubmRLcCNJAeIT0KSYc7LujxeC9bG9o64u7enSnj62Vyjv_83wl3CuqwA-nDVXMQwvvrjswPxyfrSaEqEwbxT7DXtvpsQ |
CitedBy_id | crossref_primary_10_1016_j_bbagen_2006_09_026 crossref_primary_10_1016_j_amjmed_2009_03_040 crossref_primary_10_1515_cclm_2022_0423 crossref_primary_10_1016_j_amjmed_2008_03_011 crossref_primary_10_1016_j_amjmed_2015_03_009 crossref_primary_10_1016_j_revmed_2009_12_019 crossref_primary_10_2174_1573397118666220325110737 crossref_primary_10_1097_RHU_0b013e318289e06e crossref_primary_10_1016_j_revmed_2014_09_007 |
Cites_doi | 10.1016/0016-5085(79)90384-6 10.1515/CCLM.2005.001 10.1001/archinte.1964.00280110128024 10.1016/S0025-6196(12)65200-8 10.1016/0016-5085(87)90125-9 10.1016/S0140-6736(89)91078-7 10.1046/j.1365-2249.2000.01210.x 10.1016/0190-9622(91)70048-7 10.1182/blood.V10.9.945.945 10.1159/000208756 10.1016/0016-5085(92)91112-H 10.1016/S0140-6736(86)90111-X 10.1046/j.1365-2141.1996.4791016.x 10.1111/j.1365-2796.1993.tb00752.x 10.1111/j.1442-200x.2005.02039.x 10.1056/NEJM199406303302601 10.1056/NEJM196804112781503 10.1111/j.1365-2559.1992.tb00360.x 10.1159/000418554 10.7326/0003-4819-85-4-464 10.1152/ajpheart.00885.2004 10.1002/jca.2920070209 10.1093/ajcp/58.5.524 10.1093/rheumatology/35.1.102 10.1111/j.1365-2141.1994.tb05003.x |
ClassificationCodes | R5 |
ContentType | Journal Article |
Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. 2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006 |
Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: 2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006 |
DBID | 2RA 92L CQIGP W91 ~WA CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 2B. 4A8 92I 93N PSX TCJ 5PM |
DOI | 10.3748/wjg.v12.i10.1621 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous |
EISSN | 2219-2840 |
EndPage | 1625 |
ExternalDocumentID | wjg200610020 10_3748_wjg_v12_i10_1621 16570358 21590469 |
Genre | Journal Article |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CDYEO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 4A8 PSX 5PM |
ID | FETCH-LOGICAL-c450t-ffa55b4f529c829dfcd11ef23630c43d4b6f77a65e62185a791bfba2832489aa3 |
IEDL.DBID | RPM |
ISSN | 1007-9327 |
IngestDate | Fri Sep 01 02:36:13 EDT 2023 Tue Feb 13 23:29:29 EST 2024 Fri Oct 25 21:54:29 EDT 2024 Fri Aug 23 00:28:07 EDT 2024 Wed Oct 16 00:47:24 EDT 2024 Thu Nov 24 20:29:55 EST 2022 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 10 |
Keywords | Inflammatory bowel disease Acute colitis Cryofibrinogen Trypsin inhibitor Trypsin inhibitor antibody |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c450t-ffa55b4f529c829dfcd11ef23630c43d4b6f77a65e62185a791bfba2832489aa3 |
Notes | Inflammatory bowel disease Inflammatory bowel disease; Cryofibrinogen;Trypsin inhibitor; Trypsin inhibitor antibody; Acute colitis Trypsin inhibitor 14-1219/R Trypsin inhibitor antibody Acute colitis R441 Cryofibrinogen ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Telephone: +81-729-585566 Fax: +81-729-585564 Author contributions: All authors contributed equally to the work. Correspondence to: Dr. Koji Sawada. MD, PhD, Department of Gastroenterology, Fujimoto Hospital Medicine, 3-15-27 Konda Habikino, Osaka 583-0857, Japan. f-sawada@leaf.ocn.ne.jp |
OpenAccessLink | https://doi.org/10.3748/wjg.v12.i10.1621 |
PMID | 16570358 |
PQID | 67810671 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4124298 wanfang_journals_wjg200610020 proquest_miscellaneous_67810671 crossref_primary_10_3748_wjg_v12_i10_1621 pubmed_primary_16570358 chongqing_backfile_21590469 |
PublicationCentury | 2000 |
PublicationDate | 2006-03-14 |
PublicationDateYYYYMMDD | 2006-03-14 |
PublicationDate_xml | – month: 03 year: 2006 text: 2006-03-14 day: 14 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationTitle_FL | WORLD JOURNAL OF GASTROENTEROLOGY |
PublicationYear | 2006 |
Publisher | Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan – name: Baishideng Publishing Group Co., Limited |
References | ref13 ref12 ref15 ref14 ref30 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref19 doi: 10.1016/0016-5085(79)90384-6 – ident: ref15 doi: 10.1515/CCLM.2005.001 – ident: ref22 – ident: ref4 doi: 10.1001/archinte.1964.00280110128024 – ident: ref12 doi: 10.1016/S0025-6196(12)65200-8 – ident: ref13 doi: 10.1016/0016-5085(87)90125-9 – ident: ref10 doi: 10.1016/S0140-6736(89)91078-7 – ident: ref23 doi: 10.1046/j.1365-2249.2000.01210.x – ident: ref5 doi: 10.1016/0190-9622(91)70048-7 – ident: ref30 – ident: ref1 doi: 10.1182/blood.V10.9.945.945 – ident: ref3 doi: 10.1159/000208756 – ident: ref27 doi: 10.1016/0016-5085(92)91112-H – ident: ref9 doi: 10.1016/S0140-6736(86)90111-X – ident: ref2 doi: 10.1046/j.1365-2141.1996.4791016.x – ident: ref6 doi: 10.1111/j.1365-2796.1993.tb00752.x – ident: ref21 – ident: ref24 doi: 10.1111/j.1442-200x.2005.02039.x – ident: ref17 doi: 10.1056/NEJM199406303302601 – ident: ref20 doi: 10.1056/NEJM196804112781503 – ident: ref11 doi: 10.1111/j.1365-2559.1992.tb00360.x – ident: ref28 doi: 10.1159/000418554 – ident: ref26 doi: 10.7326/0003-4819-85-4-464 – ident: ref16 doi: 10.1152/ajpheart.00885.2004 – ident: ref18 – ident: ref29 doi: 10.1002/jca.2920070209 – ident: ref25 doi: 10.1093/ajcp/58.5.524 – ident: ref8 doi: 10.1093/rheumatology/35.1.102 – ident: ref7 doi: 10.1111/j.1365-2141.1994.tb05003.x – ident: ref14 |
SSID | ssj0023352 |
Score | 1.8849211 |
Snippet | AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).
METHODS: CF was assayed in 284 subjects: 61 with active and 63... To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). CF was assayed in 284 subjects: 61 with active and 63 with inactive... AIMTo investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODSCF was assayed in 284 subjects: 61 with active and 63 with... R5; AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODS: CF was assayed in 284 subjects: 61 with active and... AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63... |
SourceID | pubmedcentral wanfang proquest crossref pubmed chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1621 |
SubjectTerms | Adolescent Adult Antibodies - blood Biomarkers - blood Blood Sedimentation C-Reactive Protein - metabolism Chronic Disease Cryoglobulins - metabolism Female Fibrinogen - metabolism Fibrinogens, Abnormal - metabolism Humans Inflammatory Bowel Diseases - blood Inflammatory Bowel Diseases - physiopathology Male Middle Aged Rapid Communication Trypsin Inhibitors - blood 冷纤维蛋白原 疾病炎症 等离子体 药物抗体 |
Title | Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous |
URI | http://lib.cqvip.com/qk/84123X/200610/21590469.html https://www.ncbi.nlm.nih.gov/pubmed/16570358 https://search.proquest.com/docview/67810671 https://d.wanfangdata.com.cn/periodical/wjg200610020 https://pubmed.ncbi.nlm.nih.gov/PMC4124298 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSgguCMQrlFIfuHDIbmI7Dx9R1aqq1KoHKvUWbMdeAhvvdnfpin_PjOMUVr1xTSzLmZl4vvGMvyHkU80kU0oin3buUuGcSGvFJF7wUTxTmWGhmvDyqjy_ERe3xe0eKca7MKFo3-hu4uf9xHffQ23lsjfTsU5sen15gh2Tmayn-2QfDHQM0WOUhZeIQoozq1IAJ9WQm0SWlen2x2xyn7NJh1tFyUKXGCz94Njw_SlsN352Bw5j10U9wp2PyyefbJV3ys_-8UxnL8jzCCnpl2HpL8me9a_It9O5vQcc2dIl4ONeUbP6DXakV51fgM3QztNIqbqmeBZLVdj44LkDG-lD7p3qxdbOaczh0G5N-8VKR1rX1-Tm7PTryXkauymkRhTZJnVOFYUWrmDSgIZaZ9o8t47xkmdG8Fbo0lWVKgsLkqkLVclcO62wlZGopVL8DTnwC2_fEcolL43NLdcmxwkBdBqlRAvYkhumRUIOH4QJ3tj8RI6pBsCFxGg8IZ9H8TbLgVKjgVAENdSAhiBsZ02HsQmsIyHHo_wbsHtMZihv4SMbcLLIfgcj3g7a-DtXVGlCqh09PQxARu3dN2BogVk7GlZCjqJGm_hHr3FlePqCjLXZ-_-e-ZA8G85weJqLD-Rgs_pljwDVbPTHYMV_ACa0-E0 |
link.rule.ids | 230,315,730,783,787,888,27938,27939,53806,53808 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwENaUMkx74TG8TCnVgQsHO7Ykv45Mp50ATYdDy_QmJEUKprGSJmkz8OvZ9aMQeoJr7NFY-Vbab7Wrbwl5W7CSKVWinnbiQuGcCAvFSrzgo3isYsOaasLRaTY8Fx8v0ostkvZ3YZqifaOryE_ryFffmtrKeW0GfZ3Y4PPoEDsms7IY3CP3Yb3GWR-kd3EWXiNqkpxxHgI9ydvsJOqsDNbfJ9FNwqIKN4uMNX1isPiDY8v3Hdhw_OQKXMamk7rDPO8WUD5YK--Un_zhm44fkS_9rNqSlMvoeqUj8_Mvwcd_nvZj8rBjq_R9-_gJ2bL-Kfl6NLU3QFHHdA7Uu1bULH6AiepF5WdgjrTytFNrXVI85qWq2VPhdwfmVzdpfapnazulXXqIVktazxa6U4x9Rs6Pj84Oh2HXqCE0Io1XoXMqTbVwKSsNgD92Zpwk1jGe8dgIPhY6c3mustTCX16kKi8T7bTCLkmiKJXiz8m2n3n7klBe8szYxHJtEhwQ-KxRSoyBtnLDtAjI3i1K4OjNJcpXSeAtJQb6AXnX4ybnrVqHhCgHoZcAvQToZYVhD3xHQA56YCUsKcyTKG9hkhL8NwrrwRsvWph_j9XZSkDyDQO4fQHFujefAJiNaHcHXkD2O1OR3WaxxC_Dgx0Uw41f_ffIB2RneDY6kScfTj_tkd32qIiHiXhNtleLa7sP5Gml3zRL5RdbXRpS |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwENZAGR4XHsPLlFIduHCwY0vy68iUZsqjnR7oTIeLkGQpmMZKSNJm4Nez60dp6K3XWKOx8q2032rX3xLytmAlU6pEPe3EhcI5ERaKlfiBj-Kxig1rqwkPj7KDE_HpND290uqrLdo3uo78tIl8_aOtrZw3ZjTUiY2OD_ewYzIri9G8cqPb5A7s2bgYAvU-1sJPidpEZ5yHQFHyLkOJWiuj9c9JdJGwqMYDI2NtrxgsAOHY9v0-HDp-8gvcxqajusY-rxdR3l0r75SfXPFP40fk27CyrizlLDpf6cj8-U_08UZLf0we9qyVvu-GPCG3rH9Kvu9P7QVQ1YrOgYI3iprFbzBVvaj9DMyS1p72qq1Lite9VLVnK_zuwAybNr1P9Wxtp7RPE9F6SZvZQvfKsc_IyXj_695B2DdsCI1I41XonEpTLVzKSgNGUDlTJYl1jGc8NoJXQmcuz1WWWvjbi1TlZaKdVtgtSRSlUvw52fIzb18SykueGZtYrk2CEwKvNUqJCugrN0yLgGxfIgUO35yhjJUE_lJiwB-QdwN2ct6pdkiIdhB-CfBLgF_WGP7AewRkdwBXwtbCfInyFhYpwY-jwB6MeNFB_W-u3l4Ckm8YweUAFO3efAKAtuLdPYAB2enNRfaHxhLfDC94UBQ3fnXjmXfJveMPY_nl49HnbfKguzHiYSJek63V4tzuAIda6TftbvkLHuYc0g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevated+plasma+cryofibrinogen+in+patients+with+active+inflammatory+bowel+disease+is+morbigenous&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Sawada%2C+Koji&rft.au=Takahashi%2C+Ryouki&rft.au=Saniabadi%2C+Abbi+R&rft.au=Ohdo%2C+Maiko&rft.date=2006-03-14&rft.issn=1007-9327&rft.volume=12&rft.issue=10&rft.spage=1621&rft.epage=1625&rft_id=info:doi/10.3748%2Fwjg.v12.i10.1621&rft.externalDBID=NO_FULL_TEXT |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fwjg%2Fwjg.jpg |